H.Res. 1147 is a House resolution that recognizes a historical record of abuses in women’s health — including coerced sterilizations, contraceptive testing in Puerto Rico, and chronic dismissal of women’s pain — and explicitly names populations disproportionately affected: Black, indigenous, immigrant, LGBTQ+, disabled, and low-income women.
The resolution affirms the need for patient-centered approaches (shared decision-making, procedural transparency, patient education), calls for expanded access to reproductive and gynecological care, and urges increased federal investment in women’s health research and institutional accountability. While the measure does not itself create new funding or regulatory authority, it establishes a congressional statement of priorities that can shape oversight, appropriations debates, research agendas, and clinical guidance.
At a Glance
What It Does
H.Res. 1147 formally records Congress’s recognition of historical and ongoing mistreatment of women in medical settings and affirms the federal government’s duty to advance patient-centered, autonomy-respecting care. The text lists specific shortcomings (dismissed pain, coercive testing, sterilization) and calls for shared decision-making, research expansion, broader access, and accountability.
Who It Affects
The resolution is directed at federal policymakers, health agencies, researchers, clinicians, hospitals, and advocacy organizations, and it explicitly centers groups that scholars and advocates identify as disproportionately harmed: Black, indigenous, immigrant, LGBTQ+, disabled, and low-income women. It also signals priorities that could influence funders and medical educators.
Why It Matters
As a nonbinding House statement, the resolution doesn't change law but shapes the policy conversation—providing congressional cover for appropriations, oversight, and guidance that prioritize women’s health research, equity, and clinical practice reforms. For compliance officers and health system leaders, it signals heightened scrutiny on how institutions treat pain and autonomy in women’s care.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The resolution opens with a series of "whereas" findings that place contemporary clinical problems in historical context. It enumerates documented abuses—forced sterilizations of Black, indigenous, immigrant, and disabled women, coercive contraceptive testing in Puerto Rico, and legal regimes that required spousal or state approval for reproductive decisions—and links those histories to present-day patterns of dismissed pain and delayed diagnoses.
The operational core of the text is five short "resolved" clauses. They (1) recognize those injustices, (2) honor the women affected, (3) affirm the need for shared decision-making and patient-centered reproductive and gynecological care (explicitly naming patient education, procedural transparency, and expanded research), (4) commit Congress to expanding access, strengthening protections for bodily autonomy, increasing federal investment in women’s health research, and holding institutions accountable for bias and harm, and (5) emphasize ending the normalization of pain and addressing implicit and structural bias.Because H.Res. 1147 is a House resolution rather than a statute, it does not appropriate funds or alter regulatory authority.
Its practical effect would be political and programmatic: it establishes congressional priorities that lawmakers, appropriators, agency leaders, and courts can cite. That makes the resolution a blueprint for future oversight letters, appropriations riders, grant priorities at NIH and CDC, and guidance from federal health agencies, even though it does not itself mandate those actions.For clinicians and health systems, the resolution signals that Congress expects attention to patient education, decision-making processes, and research into understudied women’s health conditions.
For researchers and funders, it legitimizes arguments for targeted investment and disaggregated data collection on outcomes for the populations named. For advocacy organizations, the resolution provides a formal congressional acknowledgment they can use to press for concrete policy changes and resources.
The Five Things You Need to Know
The resolution explicitly identifies historical abuses: coerced sterilizations and the contraceptive-pill testing on Puerto Rican women are cited by name.
It lists specific populations disproportionately harmed—Black, indigenous, immigrant, LGBTQ+, disabled, and low-income women—rather than using generic language about "women.", Clause (3) endorses concrete practice principles—shared decision-making, patient education, and procedural transparency—as central to gynecological and reproductive care.
The text "commits" to expanding access, strengthening protections for bodily autonomy, increasing federal investment in women’s health research, and holding institutions accountable, but it does not appropriate funds or create new statutory authorities.
H.Res. 1147 was introduced by Representative Yassamin Ansari on March 30, 2026, lists multiple cosponsors, is designated H.Res. 1147 (119th Congress), and was referred to the House Committee on Energy and Commerce.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Historical record and present harms
The preamble assembles historical and contemporary findings: it ties the architecture of gynecology to documented exploitation (including forced sterilizations and nonconsensual testing) and links those histories to current clinical failures—chiefly the dismissal of women's pain. Practically, the preamble grounds the rest of the resolution in specific grievances and identifies which populations Congress is singling out for attention, thereby narrowing the focus of any follow-on policy or oversight.
Formal recognition of injustice
This clause instructs the House to recognize the injustices that deny women dignity and respect. On its face this is declaratory: it establishes an official congressional finding that can be cited in oversight, hearings, and budget justifications. That recognition makes it harder for federal actors to ignore or downplay institutional bias when designing programs or defending funding decisions.
Affirmation of patient-centered care and research
Clause (3) specifies practice-level goals: shared decision-making, procedural transparency, patient education, and expanded research on women’s conditions. Those are programmatic priorities rather than regulatory mandates; agencies like HHS and NIH could use the language to justify targeted grant solicitations, clinical guidance, or training requirements tied to federal funding.
Commitment to access, autonomy, research investment, and accountability
This clause bundles policy aims—access expansion, protections for bodily autonomy, increased federal research investment, and institutional accountability—into a single congressional commitment. The clause does not define metrics, funding sources, or enforcement mechanisms; instead it creates a congressional statement that can be invoked in appropriations debates, oversight hearings, and regulatory rulemaking to press agencies and institutions for tangible follow-through.
Ending the normalization of pain and addressing bias
The final clause directs attention to the cultural and structural forces that normalize women's pain and implicit bias in care. Its language frames future remedies as both clinical (changes to practice and guidelines) and systemic (training, research, and institutional reforms). The clause implicitly calls for measurement and monitoring of bias—an area where policymakers will need to define indicators and data standards if they want to convert the resolution’s intent into action.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Marginalized women named in the text (Black, indigenous, immigrant, LGBTQ+, disabled, low-income): the resolution elevates their specific experiences and strengthens advocacy arguments for targeted research, services, and remedies.
- Researchers and academic centers focused on women's health: the resolution legitimizes calls for expanded funding and attention to understudied gynecological and reproductive conditions.
- Advocacy and civil-rights organizations: they gain a congressional finding they can cite in campaigns, litigation, and requests for oversight or redress.
- Clinicians and medical educators who adopt patient-centered practices: the resolution provides policy cover for curricular changes, shared-decision tools, and investments in patient education.
- Federal public health agencies and funders (NIH, HRSA, CDC): they receive a clear congressional signal that women’s health research and equity should be a priority, which can guide grant solicitations and program designs.
Who Bears the Cost
- Health systems and hospitals: may face increased expectations for documentation, transparency, training, and potential oversight costs to demonstrate compliance with patient-centered standards.
- Federal agencies (HHS, NIH, CDC): pressured to act without guaranteed new appropriations, agencies could absorb administrative burdens to develop guidance, data collection, and research priorities.
- Medical institutions and researchers implicated in past abuses: universities, hospitals, and research programs may confront reputational damage, demands for investigation, and potential legal or policy responses.
- State governments with restrictive reproductive policies: the federal affirmation of autonomy could intensify interstate policy and legal friction, requiring states and providers to navigate conflicting norms.
- Individual clinicians: increased scrutiny and expectations to change practice patterns could impose training costs and alter standard-of-care conversations with patients.
Key Issues
The Core Tension
The central dilemma of H.Res. 1147 is symbolic recognition versus concrete action: Congress can—and here does—name historical abuse and elevate patient-centered principles, but without appropriation language, statutory mandates, or clarified agency authority, the resolution risks remaining a moral statement. That creates a trade-off between immediate political affirmation of dignity and the harder, costlier work of funding, regulation, and enforcement required to change clinical practice and institutional behavior.
H.Res. 1147 is principally declaratory. It names problems and signals congressional priorities but does not create binding legal duties, appropriate money, or amend statutes.
That gap is the practical problem: without defined funding streams, metrics, or regulatory hooks, the resolution's goals depend on follow-on legislation, appropriations, or agency action to become material. Expecting agencies to deliver on expanded access or to "hold institutions accountable" without clarifying authorities or money creates a risk that the resolution will remain aspirational.
The resolution also leaves several key implementation questions unanswered. It urges expanded research and data collection but does not specify who will set research priorities, how data will be disaggregated, or what privacy safeguards will govern sensitive reproductive and health information.
Efforts to address "dismissed pain" will require standardized measurement tools, clinical training, and longitudinal data—tasks that are technically and politically challenging. Finally, by tying federal recognition of autonomy to a national debate over reproductive rights, the resolution raises the possibility of legal and administrative conflict with state laws that limit certain reproductive services, creating a jurisdictional and policy tension the text does not resolve.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.